
Single dose of STX-1150 prototype lowered LDL-C by >50% for at least two years in non-human primates without permanent DNA modification, supporting the potential for ultra-long-acting cholesterol control with reduced treatment burden; repeat dosing in NHPs enabled further LDL-C lowering while maintaining tolerability
STX-1200 surrogate achieved >95% Lp(a) reduction in non-human primates, without detectable off-target editing in primary human hepatocytes, reinforcing the potential for a potent and precise one-time Lp(a)-lowering therapy designed to recapitulate genetic protection of low Lp(a)
Results reinforce Scribe’s approach to addressing a critical unmet need in cardiovascular care: ultra-long-acting therapies designed to sustainably and substantially lower atherogenic lipoproteins and empower patients to prevent disease before it develops
ALAMEDA, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics" or "the Company") (NASDAQ:SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, reported updated preclinical data from its STX-1150 and STX-1200 programs at the American Heart Association (AHA) Scientific Sessions 2026. The findings bolster Scribe’s strategy to develop ultra-long-acting genetic medicines targeting key lipid drivers of atherosclerotic cardiovascular disease (ASCVD).
Cardiovascular risk accumulates over decades of exposure to elevated atherogenic lipids, making early and sustained lipid lowering critical. The efficacy of existing LDL-C-lowering therapies depends on lifelong treatment persistence, but 50 to 70% of patients discontinue certain therapies within one year. Meanwhile, about one in five people have genetically elevated Lp(a), an independent and causal ASCVD risk factor with no approved therapies. Scribe's STX-1150 and STX-1200 programs aim to address these challenges by translating the protective effects of naturally occurring human genetic variants into durable genetic medicines.